Explore the vast range of titles available.

Patients with cancer are at increased risk of hospitalisation and mortality following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, the SARS-CoV-2 phenotype evolution in patients with cancer since 2020 has not previously been described. We therefore evaluated SARS-CoV-2 on a UK populationscale from 01/11/2020-31/08/2022, assessing case-outcome rates of hospital assessment(s), intensive care admission and mortality. We observed that the SARS-CoV-2 disease phenotype has become less severe in patients with cancer and the non-cancer population. Case-hospitalisation rates for patients with cancer dropped from 30.58% in early 2021 to 7.45% in 2022 while case-mortality rates decreased from 20.53% to 3.25%. However, the risk of hospitalisation and mortality remains 2.10x and 2.54x higher in patients with cancer, respectively. Overall, the SARS-CoV-2 disease phenotype is less severe in 2022 compared to 2020 but patients with cancer remain at higher risk than the non-cancer population. Patients with cancer must therefore be empowered to live more normal lives, to see loved ones and families, while also being safeguarded with expanded measures to reduce the risk of transmission.

Introduction/BackgroundOur aim was to analyse the PTV used for cervical external beam radiotherapy and to determine whether smaller margins could be used without affecting clinical target volume (CTV) coverage to reduce toxicity.The significant organ motion during pelvic radiotherapy is well recognised and locally the INTERLACE protocol for IGRT using intensity modulated radiotherapy (IMRT) has been adopted with 2cm or 3cm PTV set-up margin with a ‘plan of the day’ model.MethodologyAll patients receiving radical definitive radiotherapy for cervical cancer at the Royal Devon and Exeter Hospital between 1/3/2021 and 31/12/2021 were included (n=13). They received 45 gray (6/13) or 55 gray (7/13) in 25 fractions. The radiographer-led choice between 2cm or 3cm margins with daily on-set cone beam computed tomography (CBCT) was reviewed. Based on CBCT, a margin calculation was performed to determine what margin was required to cover the disease.ResultsResults showed 23.1% (3/13) of patients were adequately treated with 2cm margin throughout, described as non-movers. These 3 patients could have been adequately treated with a 1.5cm margin; a 1cm margin would cover 77.3% of fractions. The remaining 10 patients required the 3cm margin for 15.9% of fractions (mean 3.9/25, range 2–8). For these patients a 1cm margin would cover 31.8% of fractions and 1.5cm 66.6%.ConclusionIn conclusion a smaller set-up margin can be utilised, particularly in ‘non-movers’, without compromising disease coverage. Reducing the PTV allows decreased dose to organs at risk, reducing likelihood of toxicity but further analysis of dosimetry and radiographer plan selection is requiredDisclosuresNil

The COVID-19 pandemic has led to a range of novel and adaptive research designs. In this perspective, we use our experience coordinating the National COVID Cancer Antibody Survey to demonstrate how a balance between speed and integrity can be achieved within a hyper-accelerated study design. Using the COVID-19 pandemic as an example, we show this approach is necessary in the face of uncertain and evolving situations wherein reliable information is needed in a timely fashion to guide policy. We identify streamlined participant involvement, healthcare systems integration, data architecture and real-world real-time analytics as key areas that differentiate this design from traditional cancer trials, and enable rapid results. Caution needs to be taken to avoid the exclusion of patient subgroups without digital access or literacy. We summarise the merits and defining features of hyper-accelerated cancer studies.

If any athlete with cerebral palsy has an injury or spasm causing a change of tone in the muscle - let'say it's a spasticity in the muscle through nerve damage - we are aware of it and it is often treated by the specialist who deals with them, as they know the athlete's body.